Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OSE Immunotherapeutics To Bolster R&D, Post-Janssen Option

Executive Summary

The exercising by Janssen Biotech of an option to develop OSE Immunotherapeutics’ Phase II-ready antibody fragment for autoimmune and transplant-associated disorders will give an early boost to the French biotech that only completed a merger several weeks ago.

You may also be interested in...



French Immunotherapy Leader To Be Born From OSE Pharma-Effimune Merger

Innovation overload: JNJ talks new science born from old world business strategy

Proximity is the key for future developments in science, Johnson and Johnson's UK innovation head Patrick Verheyen has told Scrip in a discussion surrounding the big pharma's 2014 goals for its globally scattered innovation centers, since their launch nearly a year ago.

Pipeline Watch: Phase III Readouts In Liver Diseases, COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Related Companies

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel